Coeur Mining

ROCKVILLE, Md. and SUZHOU, China , Nov. 17, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that a New Drug Application (NDA) for its inhouse developed investigational novel Bcl-2 selective inhibitor, lisaftoclax (APG-2575), for the treatment of patients with relapsed or refractory (r/r) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) has been accepted and recommended the Priority Review designation by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA).» Mehr auf prnewswire.com

NEW YORK, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Coeur Mining, Inc. ( NYSE : CDE ), relating to the proposed merger with SilverCrest Metals Inc. Under the terms of the agreement, holders of SilverCrest Common Shares will receive 1.6022 shares of Coeur Common Stock in exchange for each share held. Upon completion of the Arrangement, existing Coeur stockholders will own approximately 63% of outstanding Coeur Common Stock and existing SilverCrest shareholders will own approximately 37% on a fully diluted basis.» Mehr auf globenewswire.com

Exploring how investors can use a Zacks screen to help find some of the best Zacks Rank #1 (Strong Buy) stocks to buy in November and throughout the final stretch of 2024.» Mehr auf zacks.com